JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.26 -1.56

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.26

Максимум

1.32

Ключови измерители
By Trading Economics
Приходи	2.7M -24M
EPS	-0.354
Служители	49
EBITDA	-5.3M -28M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+106.98% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.2M 80M
Предишно отваряне	2.82
Предишно затваряне	1.26

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Australian Flash PMI Bounce in April Conceals Deeper Worries

22.04.2026 г., 23:33 ч. UTC

Печалби

SK Hynix Posts Record Quarterly Results Amid AI Boom

22.04.2026 г., 22:40 ч. UTC

Печалби

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22.04.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22.04.2026 г., 21:11 ч. UTC

Печалби

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22.04.2026 г., 21:01 ч. UTC

Печалби

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22.04.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.04.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22.04.2026 г., 23:16 ч. UTC

Печалби

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22.04.2026 г., 23:15 ч. UTC

Печалби

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22.04.2026 г., 22:54 ч. UTC

Печалби

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22.04.2026 г., 22:54 ч. UTC

Печалби

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22.04.2026 г., 22:52 ч. UTC

Печалби

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22.04.2026 г., 22:51 ч. UTC

Печалби

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22.04.2026 г., 22:31 ч. UTC

Печалби

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22.04.2026 г., 22:31 ч. UTC

Печалби

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22.04.2026 г., 22:30 ч. UTC

Печалби

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22.04.2026 г., 22:30 ч. UTC

Печалби

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22.04.2026 г., 22:29 ч. UTC

Печалби

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22.04.2026 г., 22:28 ч. UTC

Печалби

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22.04.2026 г., 22:28 ч. UTC

Печалби

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22.04.2026 г., 22:27 ч. UTC

Печалби

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22.04.2026 г., 22:06 ч. UTC

Пазарно говорене

Печалби

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22.04.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22.04.2026 г., 21:47 ч. UTC

Печалби

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22.04.2026 г., 21:37 ч. UTC

Печалби

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22.04.2026 г., 21:34 ч. UTC

Печалби

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22.04.2026 г., 21:29 ч. UTC

Печалби

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22.04.2026 г., 21:20 ч. UTC

Пазарно говорене

Печалби

Tesla Expands Manufacturing to Chips -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

106.98% нагоре

12-месечна прогноза

Среден 2.67 USD 106.98%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.